Drug intelligence / Profile preview

MK-3577

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK‑3577 is an orally active small molecule glucagon receptor antagonist that was developed by Merck & Co for the treatment of type 2 diabetes mellitus. The drug acts by blocking the glucagon receptor (GCGR), thereby inhibiting glucagon-mediated increases in hepatic glucose production, which is a key mechanism in the pathogenesis of type 2 diabetes. In preclinical and phase II clinical studies, MK‑3577 demonstrated efficacy in lowering blood glucose and showed an acceptable safety profile. However, development was discontinued after phase II trials[2][3][4][5].

Other names: SCHEMBL826813SCHEMBL-826813SCHEMBL 826813BDBM50360584BDBM-50360584BDBM 50360584AKOS040748934AKOS-040748934AKOS 040748934DB14957DB-14957DB 14957HY-107129HY107129HY 107129Q27896057Q-27896057Q 27896057

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on MK-3577.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-3577.

Explore the full profile